NCT02762578View on ClinicalTrials.gov

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

543

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

May 19, 2017

Study Completion Date

June 19, 2017

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec/insulin aspart

Twice daily subcutaneous (sc, under the skin) injection.

DRUG

biphasic insulin aspart

Twice daily subcutaneous (sc, under the skin) injection.

Trial Locations (42)

100029

Novo Nordisk Investigational Site, Beijing

100071

Novo Nordisk Investigational Site, Beijing

100101

Novo Nordisk Investigational Site, Beijing

100191

Novo Nordisk Investigational Site, Beijing

100700

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

130021

Novo Nordisk Investigational Site, Changchun

130033

Novo Nordisk Investigational Site, Changchun

130041

Novo Nordisk Investigational Site, Changchun

136000

Novo Nordisk Investigational Site, Siping

200040

Novo Nordisk Investigational Site, Shanghai

200072

Novo Nordisk Investigational Site, Shanghai

200080

Novo Nordisk Investigational Site, Shanghai

200240

Novo Nordisk Investigational Site, Shanghai

201199

Novo Nordisk Investigational Site, Shanghai

210011

Novo Nordisk Investigational Site, Nanjing

210012

Novo Nordisk Investigational Site, Nanjing

210029

Novo Nordisk Investigational Site, Nanjing

212001

Novo Nordisk Investigational Site, Zhenjiang

213003

Novo Nordisk Investigational Site, Changzhou

215004

Novo Nordisk Investigational Site, Suzhou

215006

Novo Nordisk Investigational Site, Suzhou

230001

Novo Nordisk Investigational Site, Hefei

230022

Novo Nordisk Investigational Site, Hefei

250013

Novo Nordisk Investigational Site, Jinan

300052

Novo Nordisk Investigational Site, Tianjin

300121

Novo Nordisk Investigational Site, Tianjin

330006

Novo Nordisk Investigational Site, Nanchang

350001

Novo Nordisk Investigational Site, Fuzhou

350025

Novo Nordisk Investigational Site, Fuzhou

400016

Novo Nordisk Investigational Site, Chongqing

404000

Novo Nordisk Investigational Site, Chongqing

510080

Novo Nordisk Investigational Site, Guangzhou

510120

Novo Nordisk Investigational Site, Guangzhou

510220

Novo Nordisk Investigational Site, Guangzhou

510515

Novo Nordisk Investigational Site, Guangzhou

530007

Novo Nordisk Investigational Site, Nanning

530021

Novo Nordisk Investigational Site, Nanning

610083

Novo Nordisk Investigational Site, Chengdu

650101

Novo Nordisk Investigational Site, Kunming

061001

Novo Nordisk Investigational Site, Cangzhou

014010

Novo Nordisk Investigational Site, Baotou

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY